The Company's 2020 consolidated financial statements have been approved by the Board of Directors
· Issued by Sofiva Genomics Co., Ltd.
Close
Today's Information
Provided by: SOFIVA GENOMICS CO.,LTD.
SEQ_NO
1
Date of announcement
2022/03/23
Time of announcement
14:18:58
Subject
The Company's 2020 consolidated financial
statements have been approved by the Board of Directors
Date of events
2022/03/23
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/03/23
2.Date of the audit committee approved:2022/03/23
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2021/01/01~2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):508,415
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):176,813
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):35,240
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):63,693
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):56,769
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):56,976
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):2.68
11.Total assets end of the period (thousand NTD):822,301
12.Total liabilities end of the period
(thousand NTD):197,861
13.Equity attributable to owners of parent end of the
period (thousand NTD):624,231
14.Any other matters that need to be specified:None
